glp 1 agonist drugs oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies NEW: This new oral GLP-1
Description
As neurological and medical complications after stroke are not properly predicted, prevented, or dealt with, they are considered to constitute the main cause of the high morbidity and mortality associated with strokes (78)
If side effects are severe, last a long time or feel unusual, its best for people to reach out to a health care provider
PMCID: PMC4215190
A GLP-1/glucagon/gastric receptor agonist has been studied in diabetic and obese mice
[DOI] [PMC free article] [PubMed] [Google Scholar] 164.Gotfredsen CF, Molck AM, Thorup I, Nyborg NC, Salanti Z, Knudsen LB, Larsen MO
